Interestingly, mutations in ASXL2, but not ASXL1, appear to significantly co-occur with FLT3-ITD mutations in AML with t(8;21)/RUNX1-RUNX1T1 [12], suggesting a difference in their leukemogenic mechanisms. This evidence concerns the gene ASXL2 and acute myeloid leukemia.